Skip to main content
Premium Trial:

Request an Annual Quote

Verisante Posts $178,000 in Q2 Revenues on Sales of Aura Device

Premium

Verisante Technology last week reported second quarter revenues of C$178,000 ($170,000), all from sales of its Aura skin cancer detection device.

The figure follows on C$235,000 in revenues from Aura sales that the company reported in the first quarter of this year. The company launched sales of the device, which uses Raman spectroscopy to distinguish benign skin legions from malignant lesions, in January (PM 2/1/2013).

For the quarter, Verisante posted a loss of C$1.14 million and a loss of C$0.02 per share. Expenses were up 79 percent from to C$1.2 million from C$668,465 in Q2 2012. This rise, the company said, was due mainly to increases in salaries and office expenses as it added personnel and leased additional office and manufacturing space as past of its ongoing expansion of operations.

As of June, 30, Verisante had C$1.02 million in cash.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.